Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)
PHASE3CompletedINTERVENTIONAL
Enrollment
752
Participants
Timeline
Start Date
January 20, 2005
Primary Completion Date
September 5, 2005
Study Completion Date
September 5, 2005
Conditions
MeaslesMumpsVaricella
Interventions
BIOLOGICAL
M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®
Trial Locations (2)
Unknown
France
Germany
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT00432523 - Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011) | Biotech Hunter | Biotech Hunter